Tapping the Global Potential of China’s Biotech Surge

Author: Tony Proctor, Emerald Clinical Trials Chief Financial Officer

China’s biotech surge is reshaping global drug development — offering faster enrollment, deep site networks and growing innovation, but also real commercial and operational risks. From a CFO’s perspective, sponsors must distinguish inbound (add China to global studies) from outbound (China firms going global), carefully assess CRO site depth, integration, financial sustainability and regulatory strategy, and avoid low‑cost, siloed “China‑only” approaches. Success requires partners that combine local China expertise with unified global operations to capture scale while managing risk.

Read the full article on Applied Clinical Trials here.